Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data

Open Access

Peer-reviewed

Research Article

Christopher M. Black,

Affiliation Merck & Co, Inc., Kenilworth, United States of America
⨯
Eric Yu,

Affiliation IMS Health Ltd, London, United Kingdom
⨯
Eilish McCann,

Affiliation Merck Sharp & Dohme Ltd, Hoddesdon, United Kingdom
⨯
Sumesh Kachroo

* E-mail: sumesh.kachroo@merck.com

Affiliation Merck & Co, Inc., Kenilworth, United States of America
⨯

Reader Comments (0)

Ulcerative colitis
Is the Subject Area "Ulcerative colitis" applicable to this article?

Thanks for your feedback.
Dose prediction methods
Is the Subject Area "Dose prediction methods" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Health care
Is the Subject Area "Health care" applicable to this article?

Thanks for your feedback.
Corticosteroid therapy
Is the Subject Area "Corticosteroid therapy" applicable to this article?

Thanks for your feedback.
England
Is the Subject Area "England" applicable to this article?

Thanks for your feedback.
Glucocorticoid therapy
Is the Subject Area "Glucocorticoid therapy" applicable to this article?

Thanks for your feedback.
Health statistics
Is the Subject Area "Health statistics" applicable to this article?

Thanks for your feedback.